VC Roundup: Moderna Seeks Another Record-Breaking Raise; Arcus Emerges From Stealth Mode

Having raised a precedent-setting $450m venture capital round in January 2015, Moderna is well on its way to a planned $600m additional fundraising. The privately held company is keeping quiet about what it's doing with all that cash. Tioma, Nutrina and Avelas are among other firms receiving VC financing.

business card

Not every private biopharmaceutical firm can be Moderna Therapeutics LLC, bringing in hundreds of millions of venture capital dollars in a single fundraising attempt, but startups in the hot immuno-oncology field – like Tioma Therapeutics Inc. and Arcus Biosciences Inc. – continue to raise large Series A and follow-on VC rounds.

Moderna already has accumulated enough money to match the record-breaking $450m venture capital round that it closed in January 2015,...

More from Business

More from Scrip

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Rocket Comes Back To Earth With Restructuring Plan

 

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.